Technologies to prevent esophageal cancer and treat fibrosis, along with medical devices to improve IV insertion accuracy and to position and hold surgical tools have been awarded funding via the Chancellor’s Innovation Commercialization Funds.
Two of the innovations received matching funds from the Pittsburgh Life Sciences Greenhouse (PLSG) and Innovation Works, the state’s seed stage startup investment fund, to cover the costs of forming startups around the technologies.
“We are pleased to be able to provide the investigators behind these impactful innovations with critical funding to de-risk the innovations from an investor perspective and move them closer to making an impact in people’s lives,” said Innovation Institute Interim Director Evan Facher.
Rich Lunak, president and CEO of Innovation Works, said he is pleased to support the creation of two new startups that have the potential to create jobs in the region.
“Innovation Works is excited to witness the increasing number of startup-ready ideas emerging from Pitt,” he said. “The more of these companies that are seeded that take root will serve to accelerate the growth of our startup ecosystem, with Pitt leading the way in the life sciences.”
In addition to providing funding for two of the projects, Innovation Works and PLSG will provide resources, including expertise in market analysis, regulatory strategy, and management recruitment.
“This year’s Chancellor’s awards demonstrate that innovation can be both revolutionary and evolutionary,” said James Jordan, president and CEO of the PLGS. “Esophagel’s biomaterial is a revolutionary breakthrough to potentially solve a problem that has no prior solution. Steeltown Innovations brings robotics learnings into surgical tools to provide better access to patient anatomy during surgery, while simultaneously improving access and safety. The PLSG is delighted to participate in funding the potential of both these technologies.”
Projects funded in the current round include:
Fibrokine l $35,000
Fibrosing diseases are estimated to contribute to 45 percent of deaths in the U.S, affecting the heart, lungs, liver, skin and arteries. Idiopathic pulmonary fibrosis (IPF) is a disease that limits oxygen transport and leads to respiratory failure and has a 60-80 percent five-year mortality rate with no current therapeutics capable of reversing fibrosis. Pitt investigators have developed anti-fibrotic peptides have the potential to inhibit IPF through development of an aerosol inhalation delivery mechanism.
Cecelia Yates, Assistant Professor, Departments of Health Promotion and Development and Pathology
Timothy Corcoran, Associate Professor of Medicine, Bioengineering and Chemical Engineering
Zariel Johnson, Posdoctoral Associate, Department of Health Promotion and Development
Christopher Mahoney, Ph.D. candidate, Department of Bioengineering
Use of Funds
- Characterize the anti-fibrotic effects of candidate peptides in a pre-clinical IPF model with optimized delivery by aerosol inhalation
- Perform customer discovery to identify and forge relationships with industry opinion leaders and potential customers
- Engage marketing and regulatory consultants to ensure candidate peptides are optimized for future pre=clinical toxicity studies and subsequent human trials
Threadrite IV l $35,000
Current IV catheters rely on visualization of blood return to indicate vein entry and have no mechanism for assisting advancement into the vein. Approximately 90 million people in the U.S. each year require multiple attempts to establish IV access resulting in increased costs associated with employee time, patient discomfort and other adverse effects. The investigators have developed a system for administering IVs that utilizes measurement of electrical resistance of the tissue to which the needle is exposed in order to ensure accurate insertion.
William (Buddy) Clark, Professor, Department of Mechanical Engineering and Materials Science
Cameron Dezfulian, Research Faculty and Physician, Department of Critical Care Medicine
Ehsan Qaium, Ph.D. candidate, Department of Mechanical Engineering
Nicholas Krehel, Ph.D. candidate, Department of Critical Care Medicine
Denny Wist, Business Mentor
Use of Funds
- Redesign the device and electronics as guided by learnings from ongoing animal and pilot human testing
- Carry out design studies related to implementing additional features into the design
Esophagel l $75,000 (Chancellors Funds $35,000; Innovation Works $20,000; PLSG $20,000)
Esophageal cancer has a five year survival rate of only 19 percent. Despite the fact that pre-cursor conditions to the most common type of esophageal cancer, including Barrett’s esophagus, are easily identifiable, but effective treatment strategies are lacking. The investigators for Esophagel have developed an extracellular matrix that can halt progression of precancerous lesions and restore normal esophageal epithelium while mitigating damage that occurs following endoscopic removal of pre-cancerous and cancerous legions that often result from gastroesophageal reflux disease (GERD).
Stephen Badylak, Professor, Department of Surgery
Juan Naranjo, Postdoctoral Fellow
Lindsey Saldin, Graduate student, Department of Bioengineering
Jenna Dziki, Graduate student, Department of Bioengineering
Use of Funds
- Develop a clinical grade version of the hydrogel to be manufactured by a contract manufacturer
- Develop a viable regulatory strategy
- Repeat benchtop and preclinical studies with the new clinical grade hydrogel based on regulatory feedback
Steeltown Innovations l $75,000 (Chancellors Funds $35,000; Innovation Works $20,000; PLSG $20,000)
Existing devices for holding surgical tools during surgery require costly setup, teardown and adjustment time during procedures, where operating room costs average $62 per minute, and where prolonged surgical time has shown to affect patient outcomes and complication rates. The investigators have created a quick-acting tool handling system that gives the surgeon the capability of self-retaining tool positioning in about 10 seconds. The system is based on a mechanically actuated flexible arm with a tool, such as a retractor, mounted at the distal end. The disposable arm is opened, snapped onto the universal base and positioned and can transition between flexible and rigid states with the click of a button.
Jeffrey Vipperman, Professor, Departments of Mechanical Engineering and Bioengineering
Garth Elias, MD, Clinical Advisor, UPMC Mercy
Joe Marcanio, Entrepreneur in Residence, Innovation Institute
Chris Dumm, Ph.D. candidate, Department of Mechanical Engineering
Jack Bartley, Undergraduate student, Department of Mechanical Engineering
Kevin Fleishmann, Undergraduate student, Department of Mechanical Engineering
Use of Funds
- Identify advanced materials having optimal properties to reduce weight and/or size of device
- Fabricate components from advanced materials
- Perform mechanical component testing
- Form legal entity and protect intellectual property
- Contract professional design firm to develop commercial version of the electromechanical control unit of retraction system